EDIT · Insider Trading
Editas Medicine, Inc. Common Stock
Every open-market purchase and sale reported by EDIT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Daniel Scott Ory | EVP, Chief Medical Officer | A | +950,000 deriv. | — |
| 2026-09-04 | Amy Parison | SVP, Chief Financial Officer | Sell | −453 | −$1.38K |
| 2026-09-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −709 | −$2.15K |
| 2026-09-04 | Gilmore Neil O'Neill | CEO | Sell | −5,124 | −$15.56K |
| 2026-08-07 | Patrick Thomas Ellinor II | Director | A | +103,400 deriv. | — |
| 2026-08-07 | Patrick Thomas Ellinor II | Director | A | +103,400 deriv. | — |
| 2026-08-05 | Amy Parison | SVP, Chief Financial Officer | Sell | −678 | −$1.75K |
| 2026-07-29 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −4,928 | −$13.16K |
| 2026-06-22 | Jessica Hopfield | Director | A | +51,700 deriv. | — |
| 2026-06-22 | Elliott M. Levy | Director | A | +51,700 deriv. | — |
| 2026-06-22 | Andrew Hirsch | Director | A | +51,700 deriv. | — |
| 2026-06-22 | Bernadette Connaughton | Director | A | +51,700 deriv. | — |
| 2026-06-22 | David Scadden | Director | A | +51,700 deriv. | — |
| 2026-06-05 | Gilmore Neil O'Neill | CEO | Sell | −15,380 | −$41.54K |
| 2026-06-05 | Amy Parison | SVP, Chief Financial Officer | Sell | −464 | −$1.25K |
| 2026-06-05 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −731 | −$1.97K |
| 2026-03-16 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | A | +292,856 deriv. | — |
| 2026-03-16 | Amy Parison | SVP, Chief Financial Officer | A | +292,856 deriv. | — |
| 2026-03-16 | Gilmore Neil O'Neill | CEO | A | +1,015,200 deriv. | — |
| 2026-03-04 | Gilmore Neil O'Neill | CEO | Sell | −5,394 | −$10.89K |
| 2026-03-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −749 | −$1.51K |
| 2026-03-04 | Amy Parison | SVP, Chief Financial Officer | Sell | −474 | −$957 |
| 2025-12-04 | Gilmore Neil O'Neill | CEO | Sell | −5,603 | −$12.06K |
| 2025-12-04 | Amy Parison | SVP, Chief Financial Officer | Sell | −461 | −$993 |
| 2025-12-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −713 | −$1.54K |
| 2025-09-04 | Amy Parison | SVP, Chief Financial Officer | Sell | −458 | −$1.19K |
| 2025-09-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −710 | −$1.84K |
| 2025-09-04 | Gilmore Neil O'Neill | CEO | Sell | −5,592 | −$14.52K |
| 2025-08-08 | Amy Parison | SVP, Chief Financial Officer | Sell | −679 | −$1.75K |
| 2025-08-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −5,121 | −$12.76K |
| 2025-06-10 | Jessica Hopfield | Director | A | +37,500 deriv. | — |
| 2025-06-10 | Bernadette Connaughton | Director | A | +37,500 deriv. | — |
| 2025-06-10 | Elliott M. Levy | Director | A | +37,500 deriv. | — |
| 2025-06-10 | Andrew Hirsch | Director | A | +37,500 deriv. | — |
| 2025-06-10 | David Scadden | Director | A | +37,500 deriv. | — |
| 2025-06-04 | Amy Parison | SVP, Chief Financial Officer | Sell | −446 | −$769 |
| 2025-06-04 | Gilmore Neil O'Neill | CEO | Sell | −15,192 | −$26.20K |
| 2025-06-04 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −726 | −$1.25K |
| 2025-04-08 | Amy Parison | SVP, Chief Financial Officer | A | +34,672 deriv. | — |
| 2025-03-27 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | A | +345,100 deriv. | — |
| 2025-03-27 | Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | A | +345,100 deriv. | — |
| 2025-03-27 | Gilmore Neil O'Neill | CEO | A | +1,003,000 deriv. | — |
| 2025-03-05 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −2,891 | −$4.95K |
| 2025-03-05 | Gilmore Neil O'Neill | CEO | Sell | −16,632 | −$28.45K |
| 2025-03-05 | Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | Sell | −4,109 | −$7.03K |
| 2024-12-05 | Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Sell | −541 | −$1.12K |
| 2024-12-05 | Gilmore Neil O'Neill | CEO | Sell | −1,618 | −$3.36K |
| 2024-09-06 | Baisong Mei | EVP, CHIEF MEDICAL OFFICER | Sell | −518 | −$1.77K |
| 2024-09-06 | Gilmore Neil O'Neill | CEO | Sell | −1,555 | −$5.33K |
| 2024-07-26 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell | −11,886 | −$64.37K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 243,189 | $583.65K |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 133,354 | $320.05K |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 112,720 | $270.53K |
| Jessica Hopfield | Director | 67,700 | $162.48K |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 61,660 | $147.98K |
| Amy Parison | SVP, Chief Financial Officer | 13,839 | $33.21K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EDIT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.